NCT00034944 is a Phase 3 clinical trial of MK0869, aprepitant in Major Depressive Disorder, sponsored by Merck Sharp & Dohme LLC.

Who is sponsoring NCT00034944?

NCT00034944 is sponsored by Merck Sharp & Dohme LLC.

What drugs are being tested in NCT00034944?

Interventions in NCT00034944: MK0869, aprepitant, Comparator: placebo.

What condition does NCT00034944 study?

NCT00034944 studies Major Depressive Disorder.

Is NCT00034944 still recruiting?

NCT00034944 is currently completed. Last updated 5 May 2017.

Last reviewed 2017-05-05 · How we verify

NCT00034944

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063)

Completed Phase 3 Last updated 5 May 2017

What this trial tests

Phase 3 trial testing MK0869, aprepitant in Major Depressive Disorder in 495 participants. Completed in 17 December 2003.

Timeline

24 January 2002

Primary endpoint
17 December 2003

17 December 2003

Quick facts

Lead sponsor	Merck Sharp & Dohme LLC
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Masking	double
Primary purpose	treatment
Enrollment	495
Start date	24 January 2002
Primary completion	17 December 2003
Estimated completion	17 December 2003

Drugs / interventions tested

MK0869, aprepitant — full drug profile →
Comparator: placebo — full drug profile →

Conditions studied

Major Depressive Disorder — all drugs for Major Depressive Disorder →

Sponsor

Merck Sharp & Dohme LLC — full company profile →

Who can join

18 and older, any sex, with Major Depressive Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A clinical study to determine the efficacy and safety of MK0869 in the treatment of depression.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of MK0869, aprepitant

Trials testing the same drug.

NCT00090246 — 2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting ( · Phase 3 · completed
NCT00090155 — 2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting ( · Phase 3 · completed
NCT00042029 — Treatment of Patients With Major Depressive Disorder With MK0869 (0869-073) · Phase 3 · completed
NCT00035295 — Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061) · Phase 3 · completed
NCT00035009 — Treatment of Patients With Major Depressive Disorder With MK0869 (0869-059) · Phase 3 · completed

Other recruiting trials for Major Depressive Disorder

Currently open trials in the same condition.

NCT07219394 — Peer-Delivered Behavioral Activation in a CCBHC · NA · recruiting
NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
NCT06749392 — An Individual-specific Synchrony Signature · NA · recruiting
NCT07316803 — Group Intervention for Romantic Relationships in Young Adults With Severe Mental Illness · NA · recruiting
NCT07242105 — Optimizing Brain Excitability in Depression · NA · recruiting

Other Merck Sharp & Dohme LLC trials

Trials by the same sponsor.

NCT07224477 — A Clinical Study of V540A in Healthy Female Participants (V540A-005) · Phase 2 · not yet recruiting
NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT07528508 — A Clinical Trial in Healthy Participants to Study the Effect of a Single Dose of MK-8527 on Levels of Methadone (MK-8527 · Phase 1 · not yet recruiting
NCT07513376 — A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (M · Phase 3 · not yet recruiting
NCT07532304 — A Clinical Trial of MK-4646 With Bictegravir/Emtricitabine/Tenofovir Alafenamide and Dolutegravir in Healthy Adult Parti · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00034944 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Merck Sharp & Dohme LLC
Last refreshed: 5 May 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00034944.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing